Beckman Coulter accelerates blood-based Alzheimer’s testing

Kevin O’Reilly, President of Beckman Coulter Diagnostics, reflects on two years of progress since the launch of the DxI 9000 Analyzer at EuroMedLab 2023. This high-sensitivity, high-throughput immunoassay analyzer — capable of testing up to 450 samples per hour — has since been enhanced with over 61 new assays, covering key clinical areas including cardiac health, sepsis, anemia, reproductive health, and infectious disease.

In this exclusive EuroMedLab 2025 update, O’Reilly also reveals groundbreaking advancements in blood-based testing for Alzheimer’s disease, including a Breakthrough Device Designation from the FDA for Beckman Coulter’s p-tau217 / Aβ1-42 assay. This test aims to replace expensive and invasive diagnostics like PET scans and lumbar punctures with scalable, community-accessible blood testing.

Beckman Coulter’s global R&D teams are leading innovation in neurodegenerative biomarkers, collaborating with the Davos Alzheimer’s Collaborative and Global Alzheimer’s Task Force to bring precision diagnostics to more patients, sooner.

Watch now to see how Beckman Coulter is transforming access to Alzheimer’s diagnostics and redefining core lab performance.

This video was filmed at EuroMedLab2025.